Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CI-135 CAR-T in R/R AML
NCT05266950Phase 1Withdrawn
- Sponsor
- Beijing Boren Hospital
- Start
- Dec 2021
- Primary completion
- Dec 2023
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CI-135 CAR-T cells in acute myeloid leukemia (AML), sponsored by Beijing Boren Hospital. Primary endpoint: Dose-limiting toxicity at 28 days. Planned start Dec 2021; status: withdrawn.
02
Drugs
CI-135 CAR-T cells
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT05266950.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05266950.